From a 2013 [1] paper, one obstacle may be getting the government or private insurance to pay for it outside of type I DM. Exceptions noted were France and Israel. In the U.S. only an exceedingly limited percentage of patients would be able to pay for the device and long-term supplies out of pocket. Until that changes, there may be little motivation for widespread adoption (until for example a large study is published in NEJM or JAMA showing extreme benefit).
Many patients are able to achieve stable control of their glucose and HbA1c on metformin (Glucophage) alone. However especially for type II DM patient needing insulin, finely controlling glucose levels might reduce long term risks as mentioned above and in the paper [1], and a pump might indeed be far superior to the typical injected insulin regimen. Interestingly, there are trials on clinicaltrials.gov about pumps in type 2 DM sponsored by MedTronic (which makes sense) [2].
Many patients are able to achieve stable control of their glucose and HbA1c on metformin (Glucophage) alone. However especially for type II DM patient needing insulin, finely controlling glucose levels might reduce long term risks as mentioned above and in the paper [1], and a pump might indeed be far superior to the typical injected insulin regimen. Interestingly, there are trials on clinicaltrials.gov about pumps in type 2 DM sponsored by MedTronic (which makes sense) [2].
As a disclaimer, I am not an endocrinologist or internal medicine guy at all. [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920779/ [2] https://clinicaltrials.gov/ct2/show/NCT01182493